State Street’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

State Street’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,817	Closed	-$27K	–	4299
2024 Q3	$27K	Hold	7,817	–	–	﹤0.01%	4190
2024 Q2	$39.7K	Buy	7,817 +1,413	+22%	+$10.6K	﹤0.01%	4187
2024 Q1	$54.2K	Hold	6,404	–	–	﹤0.01%	4144
2023 Q4	$26.2K	Hold	6,404	–	–	﹤0.01%	4312
2023 Q3	$19.2K	Hold	6,404	–	–	﹤0.01%	4447
2023 Q2	$198K	Hold	6,404	–	–	﹤0.01%	4016
2023 Q1	$317K	Hold	6,404	–	–	﹤0.01%	3905
2022 Q4	$158K	Hold	6,404	–	–	﹤0.01%	4202
2022 Q3	$425K	Hold	6,404	–	–	﹤0.01%	3839
2022 Q2	$265K	Hold	6,404	–	–	﹤0.01%	4087
2022 Q1	$323K	Buy	6,404 +624	+11%	+$30.6K	﹤0.01%	4211
2021 Q4	$347K	Hold	5,780	–	–	﹤0.01%	4139
2021 Q3	$286K	Hold	5,780	–	–	﹤0.01%	4222
2021 Q2	$329K	Sell	5,780 -28,711	-83%	-$1.53M	﹤0.01%	4018
2021 Q1	$1.98M	Buy	34,491 +2,845	+9%	+$215K	﹤0.01%	3442
2020 Q4	$2.15M	Buy	31,646 +613	+2%	+$83.5K	﹤0.01%	3342
2020 Q3	$7.88M	Buy	31,033 +2,854	+10%	+$584K	﹤0.01%	2564
2020 Q2	$4.74M	Buy	+28,179	New	+$3.04M	﹤0.01%	2782

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LWM

Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street's BCLI Position: Q4 2024 in Review

State Street sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 7,817 shares — an estimated $27K sold.

State Street first reported a position in BCLI in Q2 2020 and held it in 18 quarters. The position peaked at $7.88M in Q3 2020. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

State Street reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
State Street sold 7,817 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $27K.
State Street first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 18 quarters.
State Street's BRAINSTORM CELL THERAPUTC position peaked at $7.88M in Q3 2020.
34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on State Street's 13F filing for Q4 2024, filed 14 Feb 2025.